Filing Flows › Verastem (VSTM) › Q2 2026 › vs Q2 2025
Verastem (VSTM) Q2 2026 vs Q2 2025 (year over year)
Verastem's revenue rose $37.9M (19×) from $2.1M in Q2 2025 to $40.1M in Q2 2026. The biggest changes: Product revenue, net +$22.9M (12×).
Verastem, Q2 2026: revenue $40.1M (19× year over year), operating margin -81.6%, net loss $34.7M, operating cash flow −$43.9M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product revenue, net | $25.1M | $2.1M | $22.9M | 12× |
| Revenue | $40.1M | $2.1M | $37.9M | 19× |
| Net loss | $34.7M | $25.9M | $8.7M | +34% |
| Costs & expenses | $74.8M | $45.9M | $28.9M | +63% |
| Operating costs | $72.8M | $45.9M | $26.9M | +59% |
| Interest & other, net | $1.1M | −$17.8M | $19.0M | — |
| Income tax | $816K | $0 | $816K | — |
| Research & development | $41.3M | $24.8M | $16.6M | +67% |
| SG&A | $27.4M | $20.7M | $6.7M | +33% |
| Other operating costs | $4.0M | $446K | $3.6M | +806% |
| Operating cash sources | $47.3M | $36.1M | $11.3M | +31% |
| Share-based compensation | $3.4M | $3.4M | $17K | +0.5% |
| Cash used in operations | $43.9M | $32.7M | $11.2M | +34% |
| Net loss absorbed | $34.7M | $25.9M | $8.7M | +34% |
| Working capital & other | $12.7M | $10.1M | $2.5M | +25% |
Questions
How much did Verastem's revenue grow year over year in Q2 2026?
Verastem's revenue rose $37.9M (19×) from $2.1M in Q2 2025 to $40.1M in Q2 2026.
What drove Verastem's revenue change in Q2 2026?
Product revenue, net +$22.9M (12×).